Last reviewed · How we verify
GRT-C903
At a glance
| Generic name | GRT-C903 |
|---|---|
| Sponsor | Gritstone bio, Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer (PHASE1)
- A Study of a Personalized Cancer Vaccine Targeting Shared Neoantigens (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |